The estimated Net Worth of Rachel K. King is at least $2.69 Milión dollars as of 12 June 2024. Ms. King owns over 6,670 units of GlycoMimetics Inc stock worth over $3,027 and over the last 11 years she sold GLYC stock worth over $0. In addition, she makes $2,689,070 as President, Chief Executive Officer, Co-Founder a Director at GlycoMimetics Inc.
Sign up
Ms. King GLYC stock SEC Form 4 insiders trading
Rachel has made over 10 trades of the GlycoMimetics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 6,670 units of GLYC stock worth $1,067 on 12 June 2024.
The largest trade she's ever made was exercising 166,759 units of GlycoMimetics Inc stock on 6 August 2019 worth over $186,770. On average, Rachel trades about 19,022 units every 126 days since 2014. As of 12 June 2024 she still owns at least 18,920 units of GlycoMimetics Inc stock.
You can see the complete history of Ms. King stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rachel King biography
Rachel K. King is the President, Chief Executive Officer, Co-Founder, Director of GlycoMimetics, Inc. Ms. King is a co-founder of our company and has served as our President and Chief Executive Officer and as a member of our Board since our inception in 2003. Previously, Ms. King was an Executive in Residence at NEA from 2001 to 2003. From 1999 to 2001, Ms. King served as a Senior Vice President of Novartis Corporation, a pharmaceutical company. Before joining Novartis, Ms. King spent 10 years with Genetic Therapy, Inc., a biotechnology company, where she served in a number of roles as part of the executive team, which included the company’s initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as Chief Executive Officer of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Ms. King previously worked at Alza Corporation, a pharmaceutical and medical systems company that was later acquired by Johnson & Johnson, as well as at Bain and Company, a management consulting firm. Ms. King has served on the board of directors of Novavax, Inc., a publicly traded biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases, since 2018. She received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School. Ms. King currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO) and served as the Chair of the Board of BIO from 2013 to 2015. She was appointed by Maryland’s governor Martin O’Malley as Chair of the Maryland Life Sciences Advisory Board and served in that capacity from 2013 to 2015. She also currently serves on the Board of the University of Maryland BioPark . She received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School.
What is the salary of Rachel King?
As the President, Chief Executive Officer, Co-Founder a Director of GlycoMimetics Inc, the total compensation of Rachel King at GlycoMimetics Inc is $2,689,070. There are no executives at GlycoMimetics Inc getting paid more.
How old is Rachel King?
Rachel King is 60, she's been the President, Chief Executive Officer, Co-Founder a Director of GlycoMimetics Inc since 2003. There are 7 older and 9 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
What's Rachel King's mailing address?
Rachel's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.
Insiders trading at GlycoMimetics Inc
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris a M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
What does GlycoMimetics Inc do?
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
What does GlycoMimetics Inc's logo look like?
Complete history of Ms. King stock trades at GlycoMimetics Inc a Novavax
GlycoMimetics Inc executives and stock owners
GlycoMimetics Inc executives and other stock owners filed with the SEC include:
-
Rachel King,
President, Chief Executive Officer, Co-Founder, Director -
Brian Hahn,
Chief Financial Officer -
Helen Thackray,
Senior Vice President - Clinical Development, Chief Medical Officer -
John Magnani,
Co-Founder, Senior Vice President, Chief Scientific Officer -
Rachel K. King,
Pres, CEO & Director -
Brian M. Hahn,
Sr. VP & CFO -
Timothy Pearson,
Independent Chairman of the Board -
Daniel Junius,
Independent Director -
Mark Goldberg,
Independent Director -
Scott Jackson,
Independent Director -
Patricia Andrews,
Independent Director -
Scott Koenig,
Independent Director -
Armand Girard,
Senior Vice President, Chief Business Officer -
Bruce Johnson,
Sr. VP & Chief Commercial Officer -
Armand Girard,
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. -
Dr. John L. Magnani,
Sr. VP of Research & Chief Scientific Officer -
Harout Semerjian,
CEO, Pres & Director -
Dr. Eric J. Feldman M.D.,
Sr. VP & Chief Medical Officer -
Christian Dinneen-Long,
VP, Corp. Counsel & Corp. Sec. -
Henry Flanner,
VP of Technical Operations -
Stephanie R. Irish,
VP of Accounting -
Partners L P/Ilbiotechnolog...,
-
Scott D Sandell,
10% owner -
Franklin H Jr Top,
Director -
Peter J Barris,
10% owner -
Michael A Henos,
Director -
M James Barrett,
Director -
Enterprise Associates 10 L ...,
-
John J. Baldwin,
Director -
Chinmaya Rath,
SVP and Chief Business Officer -
William M. Gust,
Director -
Enterprise Associates 13 Lp...,
-
Partners L P/Ilbiotechnolog...,
-
Harout Semerjian,
Chief Executive Officer -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Invus ...,
-
Bruce S Johnson,
SVP & Chief Commercial Officer -
Edwin Rock,
Chief Medical Officer